NCT07354347 Optimal Settings for Anti Tachycardia Pacing (ATP) on ICD
| NCT ID | NCT07354347 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rigshospitalet, Denmark |
| Condition | Heart Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 3,980 participants |
| Start Date | 2026-02-01 |
| Primary Completion | 2041-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 3,980 participants in total. It began in 2026-02-01 with a primary completion date of 2041-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a pragmatic, two-group, cluster randomized trial designed to compare strategies for the Anti Tachycardia Pacing (ATP)-setting in the ventricular tachyarrhythmias (VT) zone when implanting a new implantable cardioverter defibrillator (ICD) in patients with heart disease in hospitals in Denmark. The strategies are: "Burst" or "Ramp" after 1. ATP (which is always burst) in VT zone. VT zone is defined between 180-249 (up to 269 in special cases) heartbeats per minute. The ICD will give either: Burst: The ICD is programmed to give ATP with 4 bursts. Or Ramp: The ICD is programmed to give ATP with 1 burst and 3 ramps. The participating hospitals will be assigned to one of two intervention strategies for periods of 4-months. The given intervention will follow the patient/ICD throughout the life time of the ICD, but with the possibility to reprogram at any time (intention to treat). It is calculated that the study needs a total of 398 events (second to fourth ATP), which is estimated to require 3980 implanted ICDs. The participants will be followed until the end of the ICD life, which is estimated to be around 10 years.
Eligibility Criteria
Inclusion Criteria: \- ICD implantation for primary or secondary prophylactic indication Exclusion Criteria: * None * Patients can actively opt out of participation in the study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07354347 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07354347 currently recruiting?
Yes, NCT07354347 is actively recruiting participants. Contact the research team at bo.winkel@regionh.dk for enrollment information.
Where is the NCT07354347 trial being conducted?
This trial is being conducted at Copenhagen, Denmark.
Who is sponsoring the NCT07354347 clinical trial?
NCT07354347 is sponsored by Rigshospitalet, Denmark. The trial plans to enroll 3,980 participants.